Faes Farma Acquires Portuguese Firm Laboratorios Edol

• Faes Farma has signed an agreement to acquire 100% of Laboratorios Edol, a Portuguese pharmaceutical company, for €75 million.

• The acquisition is expected to double Faes Farma’s sales and EBITDA in Portugal, enhancing its ophthalmology portfolio and international presence.

Faes Farma, a Spanish pharmaceutical company, has entered into a purchase agreement to acquire the entirety of Laboratorios Edol Produtos Farmacêuticos, S.A., a Portuguese firm specializing in ophthalmology, for €75 million. 

Founded in 1952, Laboratorios Edol is recognized as a leader in Portugal’s ophthalmology sector, reporting an annual turnover exceeding €30 million in 2024. The company operates a modern production facility and offers a product portfolio that complements Faes Farma’s existing offerings. 

This strategic acquisition aims to consolidate Faes Farma’s expansion in the Portuguese market, where it has maintained a presence for over 80 years. By integrating Laboratorios Edol’s operations, Faes Farma anticipates doubling its sales and EBITDA in Portugal, while also achieving commercial and operational synergies. 

The move aligns with Faes Farma’s broader strategy of international growth and diversification into new therapeutic areas. The ophthalmology sector presents significant opportunities, driven by factors such as an ageing population and increased screen time leading to conditions like glaucoma and dry eye. 

The completion of the transaction is subject to certain conditions, which are expected to be fulfilled by the end of June 2025.